Erschienen in:
01.03.2005 | Therapy In Practice
Neurologically Presenting Wilson’s Disease
Epidemiology, Pathophysiology and Treatment
verfasst von:
Dr George J. Brewer
Erschienen in:
CNS Drugs
|
Ausgabe 3/2005
Einloggen, um Zugang zu erhalten
Abstract
Wilson’s disease is a rare autosomal recessive disease of copper accumulation and copper toxicity, due to mutations in the ATP7B gene, which leads to a failure of copper excretion in the bile. It presents clinically primarily as liver disease, psychiatric disease, neurological disease, or a combination of these. The neurological disease is a movement disorder, with abnormalities of speech, tremor, incoordination and dystonia being common features. Diagnosis of neurologically presenting patients is usually straightforward, with Kayser-Fleischer rings and a urine copper over 100 μg/day almost invariably present. In the treatment of neurologically presenting patients, penicillamine should always be avoided, because of the high risk of permanent, drug-induced, additional neurological deterioration. A new drug we have developed, tetrathiomolybdate, given for 8–16 weeks, in combination with zinc, is our first choice for treating these patients. In the absence of availability of tetrathiomolybdate, zinc or trientine are the next best choices.